29 November 2015 - It's de rigueur to launch new cancer drugs with six-figure annual price tags, and that fact is causing seismic repercussions for patients facing ever-increasing treatment costs.

For more details, go to: http://www.fool.com/investing/general/2015/11/29/insurers-dont-want-to-pay-for-pricey-cancer-meds.aspx